MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.19.03279

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Shah Nirali N, Highfill Steven L, Shalabi Haneen, Yates Bonnie, Jin Jianjian, Wolters Pamela L, Ombrello Amanda, Steinberg Seth M, Martin Staci, Delbrook Cindy, Hoffman Leah, Little Lauren, Ponduri Anusha, Qin Haiying, Qureshi Haris, Dulau-Florea Alina, Salem Dalia, Wang Hao-Wei, Yuan Constance, Stetler-Stevenson Maryalice, Panch Sandhya, Tran Minh, Mackall Crystal L, Stroncek David F, Fry Terry J

Клиническое исследование I фазыСтатьяResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort treated with CD22 chimeric antigen receptor (CAR) T cells.

PATIENTS AND

METHODS

We conducted a single-center, phase I, 3 + 3 dose-escalation trial with a large expansion cohort that tested CD22-targeted CAR T cells for children and young adults with relapsed/refractory CD22+ malignancies. Primary objectives were to assess the safety, toxicity, and feasibility. Secondary objectives included efficacy, CD22 CAR T-cell persistence, and cytokine profiling.

RESULTS

Fifty-eight participants were infused; 51 (87.9%) after prior CD19-targeted therapy. Cytokine release syndrome occurred in 50 participants (86.2%) and was grade 1-2 in 45 (90%). Symptoms of neurotoxicity were minimal and transient. Hemophagocytic lymphohistiocytosis-like manifestations were seen in 19/58 (32.8%) of subjects, prompting utilization of anakinra. CD4/CD8 T-cell selection of the apheresis product improved CAR T-cell manufacturing feasibility as well as heightened inflammatory toxicities, leading to dose de-escalation. The complete remission rate was 70%. The median overall survival was 13.4 months (95% CI, 7.7 to 20.3 months). Among those who achieved a complete response, the median relapse-free survival was 6.0 months (95% CI, 4.1 to 6.5 months). Thirteen participants proceeded to stem-cell transplantation.

CONCLUSION

In the largest experience of CD22 CAR T-cells to our knowledge, we provide novel information on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell toxicities and toxicity mitigation strategies. The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy.

Для цитирования: Shah Nirali N, Highfill Steven L, Shalabi Haneen, Yates Bonnie, Jin Jianjian, Wolters Pamela L, Ombrello Amanda, Steinberg Seth M, Martin Staci, Delbrook Cindy, Hoffman Leah, Little Lauren, Ponduri Anusha, Qin Haiying, Qureshi Haris, Dulau-Florea Alina, Salem Dalia, Wang Hao-Wei, Yuan Constance, Stetler-Stevenson Maryalice, Panch Sandhya, Tran Minh, Mackall Crystal L, Stroncek David F, Fry Terry J. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020. DOI: 10.1200/jco.19.03279.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.